Molsid company

(Biotech & Medtech)

Molsid, a young BioMed company, based in Lyon (France), develops a new generation of fluorogenic molecular probes.

17

Lorem ipsum dolor

455

Lorem ipsum dolor

+2 000

Lorem ipsum dolor

About us

Partners

Careers

Publications

News & Events

Market Needs

Modern life science and biotech/medtech applications require the detection of biocatalytical activity of a specific enzyme in live cells without the use of antibodies. However, today’s chromogenic substrates suffer from low performance and marketed fluorogenic substrates lack robustness. The use of enzyme-responsive probes releasing a precipitated signal meets significant challenges, i.e. sensitivity, fast response time, and signal retention. These advantages help identifying clearly and rapidly biomarkers for cancer and other pathogens, contaminations and antibiotic resistances. With Antimicrobial Resistance being announced to become the leading cause of death by 2050 world-wide, the need for early diagnostics is steadily growing.

Breakthrough

In 2003, Jens Hasserodt, professor of organic chemistry at ENS de Lyon, France, started a research program into the development of a new generation of pro-fluorescent, enzyme-responsive probes urgent market needs. Today, Molsid has an exclusive licence on the patent portfolio protecting this innovative molecular technology and currently growths its own patent portfolio.

Origins

Many reports of the past 20 years have highlighted the unique properties of the solid-state fluorophore HPQ, also known as “ELF 97 alcohol”. HPQ is a highly attractive candidate for the incorporation into enzyme-responsive molecular probes that furnish high sensitivity, rapid response, and signal retention. But HPQ has unfavourable chemical properties with regard to its incorporation into stable and robust molecular probes. Hence, a single probe has hitherto been marketed, responding to generic phosphatase activity. It is here that Molsid’s innovative chemical technology changes the game by offering robust probes for many enzyme activities.

ENS Lyon

Team

We are based in Lyon’s Biodistrict Gerland, on the ENS Campus, where we develop and produce the broadest range of robust fluorogenic precipitation-based probes available world-wide. We offer unsurpassed fast and sensitive fluorescence detection for a large panel of enzymes for industrial and R&D applications.

 

Anne Khoschnud

— Chairman, Co-founder

25 years of experience in Company set-up, Business strategy, Business development, Innovation management, Team and resources Management, International Marketing.

After initial linguistic and economic studies in Heidelberg, Germany, where Anne grew up, she got a Master of Project Management from Montpellier University in France. She worked in the Financial Direction of Imerys SA in Paris and in the consumer marketing department of T-Mobile International in London before joining a first start-up project in France. She co-founded 3 innovative companies in different fields (IT, optoelectronics and biomed) and worked as a business strategy consultant for 7 years. She is an occasional lecturer at 2 French top universities (ENSAM, Sorbonne). Anne co-founded Molsid in 2018 and was its CEO & Chairman until Oct 2021 before splitting the position and becoming its Chairman.

Jens Hasserodt

— Chief scientific advisor, Co-founder

30 years of experience in R&D in organic chemistry, design of molecular probes, inventor of SmartID technology, renowned scientist and lecturer, Professor at ENS Lyon

Jens obtained his PhD degree in Chemistry from Heidelberg University in Germany. He spent 7 years at the Scripps Research Institute in San Diego, CA, before joining France’s elite university Ecole Normale Supérieure in Lyon as a professor of chemistry. Ever since, he developed an international reputation for his research into the detection and characterization of enzyme activity by optical (fluorescence) and magnetic (MRI) detection using sophisticated chemical reactants. He has published over 50 peer-reviewed articles in international science journals, has filed 11 patents, and trained 17 PhD students to date. Jens is Molsid’s Chief Scientific Advisor and its main shareholder.

David Siegrist

— CEO, Shareholder

30 years of experience in Business and financial administration, Business Strategy, Finance and accounting, Team and resources management in the MedTech industry

After an initial diploma in Biology, David completed his studies with a Master in Business Administration (Development of a New MedTech Product) and a Master in Finance and Controlling.  He started his career with major players such as Merial and Serono as a Controller. He gained HR administration and management experience with medium players such as PX Therapeutics and Spineway. For Spineway, he managed the fundraising projects and an IPO. He lately started his own business and finally joined Molsid in 2020 as CFO. He became its CEO & CFO and a Shareholder of Molsid in October 2021.

Cyril Petibois

— Chief Business Officer

25 years of experience in biochemistry, R&D development, business development, international subcontracting, licencing and marketing, complex project management

Cyril got his PhD in Biochemistry at Bordeaux University and completed it with an Executive Master of Business Administration from Polytechnique. He has gained international experience with the launch and management of 2 CRO start-ups in Taiwan and managed diverse R&D and business projects at international scale, notably in Asia. He is regular lecturer at the University of Bordeaux. He joined Molsid in August 2021 as its Chief Business Officer. He is now a Shareholder and Molsid’s PYTHIA program Director.

Philippe Chabert

— Chief Operating Officer

35 years of experience in operation management in the healthcare industry, Research and Development, Manufacturing, Logistics, Supply chain, Quality Management and IT system.

Philippe got his PhD in Biochemistry at Lyon University. He started his career at bioMérieux in R&D, production and purchasing (1986-1998). He then held supply chain positions in the pharmaceutical industry successively at Bausch & Lomb then Besins Intl. Healthcare in Belgium where he led industrial and IT transfer projects before joining the French biotech company OPi in 2005. Recently, he was COO at Elsalys Biotech, a role he already held at EUSA Pharma/Jazz Pharmaceuticals and Spineway. He became Molsid’s COO and a Shareholder in April 2022.

Strategic advisory board

Christian Abraham

— Strategic Advisor

15 years+ of experience in therapeutic areas such as autoimmune, neurological, infectious diseases, and oncology in diverse industries including Biotech, Diagnostic, and Pharmaceutical.

Christian obtained his PhD in Biology at Gutenberg University (Germany) and complemented it with postdoctoral research (Dep. of Neurobiology, David Geffen School of Medicine, University of California, Dep. of Molecular & Cellular Anatomy, University Clinic Aachen). He supplemented his background with an Executive MBA from Gutenberg School of Business. He gained extensive international experience during his roles spanning Business & Portfolio development, Alliance management and Market Access. Due to his diverse background, Christian brings a well-rounded view for finding solutions on how healthcare can be made patient-centric, inclusive, and affordable. Christian is Molsid’s strategic advisor since 2018 and became a shareholder in 2021.

Pierre Morgon

— Strategic Advisor

35 years of experience in leading positions in the global life science industry in C-level positions at global level in multinational corporations and as CEO of start-up companies.

Pierre holds a Doctorate of Pharmacy, a MA in Business Law and a MBA, he is an alumnus of INSEAD and IMD. CEO of MRGN Advisors, Executive VP, Portfolio Strategy and Supranational Affairs at CanSino Biologics and Regional Partner for Switzerland at Merieux Equity Partners. He is Chairman of the Boards of Theradiag, Eurocine Vaccines, MYCB1, Adiposs, Kupando and Health Technologies Holding, and Non-Executive Director to the Boards of Vaccitech, Univercells and Amoeba. He is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is also a mentor for start-up life sciences companies. Pierre is Molsid’s strategic advisor since 2019.

Bernard Mandrand

— Strategic Advisor

40 years of experience in leading positions in the molecular biology and diagnostics industry.

Bernard holds a PhD in Biophysics and biochemistry from UCB Lyon1 in 1974. Co-founder and Chairman of several companies, Bernard is a former Scientific Director of bioMérieux and Scientific Director of Lyonbiopôle Excellence Cluster in Lyon. He co-founded and led several start-ups and spin-offs: Ademtech, Apibio (a JV between bioMérieux-CEA), Adjuvatis and GlycoBAR. Specialized in bio-analysis and microbiology, he co-authored 68 publications as well as 62 patents granted in Europe and 55 granted in the US. Bernard is a renowned expert for innovation in the life sciences sector. He is Molsid’s Strategic Advisor since its foundation in 2018.

Strategic Antimicrobial Resistance advisory board

Rafael Cantón

— PHD

Clinical Microbiology specialist, Head of the Clinical Microbiology Department at the University Hospital Ramón y Cajal in Madrid (Spain) and associated Professor of Clinical Microbiology at Complutense University in Madrid.

Prof. Rafael Cantóns research activity is developed within the Spanish Network for Research in Infectious Diseases (CIBERINFEC, https://www.ciberinfec.es/) and Institute Ramón y Cajal for Health Research (IRYCIS, http://www.irycis.org) in which he coordinates the Microbiology, Immunology and Infection Area. This activity is focussed on antimicrobial resistance mechanisms, including extended-spectrum beta-lactamases and carbapenemases, antimicrobial susceptibility testing, respiratory tract infections (mainly in bronchiectasis and cystic fibrosis), and interplay of clonal epidemiology and resistance. He is currently the clinical data coordinator of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) (former president). He has been President of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). He has published more than 600 articles in peer-review journals, 55 book chapters and had several communications on international meeting and congresses. His H factor is 96. He is member of the editorial board of Microbial Drug Resistant, Drug Resistance Updates, Diagnostic Microbiology and Infectious Diseases, Enfermedades Infecciosas y Microbiología Clinica and Revista Española de Quimioterapia journals. He is editor of the Clinical Microbiology Procedures of the SEIMC (https://seimc.org/).

Laurent Poirel

— PHD

Medical and Molecular Microbiology Unit, Faculty of Science and Medicine, University of Fribourg, Switzerland. Swiss National Reference Center for Emerging Antibiotic Resistance

Laurent Poirel is Associate Professor at the Emerging Resistance to Antibiotics Research Unit and Swiss National Reference Center for Emerging Antibiotic Resistance at the University of Fribourg. His research interests emerging mechanisms of resistance to ß-lactams, polymyxins, and quinolones in Gram-negative rods, either in human and veterinary medicine. He is specialized on the genetics of acquisition of resistance genes in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii, plasmid-mediated quinolone resistance, and polymyxin resistance determinants in Enterobacteriaceae. He has co-invented a series of rapid diagnostic tests for detection of emerging resistance traits. He is the author of ca. 600 publications in international journals, his H-index being 136. He is the Editor-in-Chief of the European Journal of Clinical Microbiology and Infectious Diseases and Associate Editor of two highly-ranked journals, i.e. Antimicrobial Agents and Chemotherapy and Journal of Antimicrobial Agents. He has been active member of the ESCMID, being a member of the Executive Subcommittee (2015-2018), co-director of two ESCMID Summer Schools (Borstel 2017 and Paris 2018), and currently member of the ESGARS Executive Committee.

Discover our solutions